Pharmacokinetics – Medxy AI

Precision Dosing of Secukinumab in Hidradenitis Suppurativa: Insights from the SUNSHINE and SUNRISE Pooled Pharmacokinetic Analysis

By MedXY 03/05/2026

This review synthesizes the 52-week pooled results from two Phase 3 trials, detailing the pharmacokinetics, safety, and biomarker responses of secukinumab in moderate-to-severe hidradenitis suppurativa.

Diabetes & Endocrinology Internal Medicine news

Once-Weekly Insulin GZR4: A Potential Paradigm Shift in Basal Insulin Therapy for Type 2 Diabetes

By MedXY 02/04/2026

A Phase 1b trial demonstrates that the once-weekly insulin GZR4 is safe, well-tolerated, and effective in lowering FPG and HbA1c in patients with T2DM, potentially offering a more convenient alternative to daily basal insulin.

Critical Care Infectious Diseases news

Precision Dosing in the ICU: Extended Infusions of Meropenem and Piperacillin Optimize Therapy During Renal Replacement

By MedXY 12/28/2025

A large-scale multinational study reveals that meropenem and piperacillin dosing during renal replacement therapy must be tailored to RRT intensity and urine output, with extended infusions significantly improving therapeutic target attainment.

HIV/AIDS news Pediatrics

Once‑Daily Dolutegravir/Lamivudine Fixed‑Dose Tablets Achieve Robust Pediatric Exposures and Reassuring Safety in the D3/PENTA 21 PK Sub‑Study

By MedXY 11/12/2025

A nested PK and safety sub‑study of D3/PENTA 21 shows once‑daily DTG/3TC dispersible and film‑coated fixed‑dose tablets deliver adequate drug exposures across WHO weight bands in children 2–<15 years, with no drug‑related discontinuations and comparable PK to historical pediatric data.

HIV/AIDS news Pediatrics

Dolutegravir from Birth: PETITE‑DTG Shows Safe, Targeted Neonatal Dosing for Term Newborns

By MedXY 11/12/2025

First randomized neonatal PK/safety data show 5 mg dolutegravir (dispersible tablet or oral film) every 48 hours for two weeks, then daily to day 28, achieves target troughs with acceptable safety in term infants born to mothers on dolutegravir-based ART.

Clinical Updates Infectious Diseases Respiratory Specialties

Optimizing Pyrazinamide Dosing in Drug-Susceptible Pulmonary Tuberculosis: Insights from a Large Phase 3 Trial

By MedXY 09/17/2025

A comprehensive analysis from the TBTC Study 31/ACTG A5349 reveals that flat dosing of pyrazinamide at 1,000 mg daily optimizes efficacy and safety, challenging current weight-banded dosing strategies for drug-susceptible tuberculosis.

Clinical Updates Diabetes & Endocrinology news Specialties

Amycretin: A Promising First-in-Class Dual GLP-1 and Amylin Receptor Agonist for Overweight and Obesity

By MedXY 09/17/2025

Amycretin, a novel dual GLP-1 and amylin receptor agonist, demonstrated safety, tolerability, and dose-proportional pharmacokinetics in adults with overweight or obesity, supporting further trials on its weight loss efficacy.

Clinical Updates Family Medicine & Nutrition Internal Medicine news Specialties

Dihydroberberine: Enhanced Absorption and Emerging Therapeutic Potential Based on Recent Clinical and Mechanistic Insights

By MedXY 08/24/2025

Dihydroberberine demonstrates superior absorption compared to berberine, suggesting enhanced pharmacological properties. Recent studies highlight its potential in metabolic and inflammatory diseases, warranting further clinical exploration.

Clinical Updates Diabetes & Endocrinology news Specialties

Recent Advances in Dihydroberberine Research: Pharmacokinetics, Mechanisms, and Clinical Potential

By MedXY 08/24/2025

This review synthesizes the latest 5-year evidence on dihydroberberine, highlighting improved bioavailability over berberine, mechanistic insights from metabolic and network pharmacology studies, and its promising clinical applications in metabolic and respiratory diseases.

Clinical Updates news Psychiatry Specialties

Long-Acting Oral Weekly Risperidone (LYN-005): Translating Pharmacokinetic Equivalence to Clinical Opportunity in Schizophrenia

By MedXY 08/03/2025

Weekly LYN-005 demonstrated pharmacokinetic equivalence to daily risperidone, sustained therapeutic levels, and manageable safety in clinically stable patients, offering a novel option to address non-adherence in schizophrenia.

Internal Medicine news Nursing & care

Why Do Some Medicines Require a ‘Loading Dose’? The Science Behind the First Double Dose

By MedXY 07/27/2025

Exploring why certain medications start with a larger first dose, the clinical evidence, common misconceptions, and practical guidelines for safe use.